Professor Jason Carroll
Professor Jason Carroll is pleased to consider applications from prospective PhD students.
We are interested in understanding how Estrogen Receptor (ER) transcription contributes to breast cancer cell growth and to response to endocrine therapies. We use genomic and proteomic tools to identify the cis-regulatory regions of the genome used by ER and to identify and characterise the proteins and co-factors that either assist or inhibit ER transcriptional activity. We have recently found that ER binding to chromatin requires a new class of proteins called Pioneer factors. We are characterising the role and properties of Pioneer factors since we believe that these may constitute a mechanism of blocking ER from binding to chromatin; an event that may permit inhibition of ER driven transcription, even in situations where tumours has acquired drug resistance. We are also involved in identifying the molecular mechanisms of action of the breast cancer drug tamoxifen in breast cancer models.
Symplectic Elements feed provided by Research Information, University of Cambridge
Mohammed H, Russell, I. A, Stark, R, Rueda, O.M, Hickey, T.E, Tarulli, G.A, Serandour, A.A.A, Birrell, S.N, Burna, A, Saadi, A, Menon, S, Hadfield, J, Pugh, M, Raj, G.V, Brown, G.D, D’Santos, C, Robinson, J.L.L, Silva, G, Launchbury, R Perou, C.M, Stingl, J, Caldas, C, Tilley, W.D and Carroll J.S. Progesterone receptor modulates estrogen receptor- action in breast cancer. Nature, 2015, 523: 313-317
Mohammed, H, D’Santos, C, Serandour, A.A, Ali, H.R, Brown, G.D, Atkins, A, Rueda, O.M, Holmes, K.A, Theodorou, V, Robinson, J.L.L, Zwart, W, Saadi, A, Ross-Innes, C.S, Chin, S-F, Menon, S, Stingl, J, Palmieri, C, Caldas, C and Carroll, J.S. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Reports, 2013, 3: 342-9
Ross-Innes, C.S, Stark, R, Teschendorff, A.E, Holmes, K.A, Ali, H.R, Dunning, M.J, Brown, G.D, Gojis, O, Ellis, I.O, Green, A.R, Ali, S, Chin, S.F, Palmieri, C, Caldas, C and Carroll, J.S. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 2012, 481: 389-93
Hurtado, A, Holmes, K.A, Ross-Innes, C.S, Schmidt, D and Carroll, J.S. FoxA1 is necessary and sufficient for programming Estrogen Receptor function and endocrine response. Nature Genetics, 2011, 43:27-33